Literature DB >> 34417356

Nicotinic aspects of the discriminative stimulus effects of arecoline.

Gail Winger1.   

Abstract

Despite the evidence that the muscarinic agonist arecoline is a drug of abuse throughout Southeast Asia, its stimulus characteristics have not been well studied. The goal of this work was to understand more about the mediation of discriminative stimulus effects of arecoline. Arecoline (1.0 mg/kg s.c.) was trained as a discriminative stimulus in a group of eight rats. The ability of various cholinergic agonists and antagonists to mimic or antagonize the discriminative stimulus effects of arecoline and to modify its rate-suppressing effects was evaluated. A muscarinic antagonist, but neither of two nicotinic antagonists, was able to modify the discriminative stimulus effects of arecoline, suggesting a predominant muscarinic basis of arecoline's discriminative stimulus effects in this assay. However, both nicotine itself and two nicotine agonists with selective affinity for the α4β2* receptor (ispronicline and metanicotine) produced full arecoline-like discriminative stimulus effects in these rats. The discriminative stimulus effects of the selective nicotine agonists were blocked by both the general nicotine antagonist mecamylamine and by the selective α4β2* antagonist, dihydro-beta-erythroidine (DHβE). Surprisingly, only DHβE antagonized the rate-suppressing effects of the selective nicotine agonists. These data indicate a selective α4β2* nicotine receptor component to the behavioral effects of arecoline. Although the nicotinic aspects of arecoline's behavior effects could suggest that abuse of arecoline-containing material (e.g. betel nut chewing) is mediated through nicotinic rather than muscarinic actions, further research, specifically on the reinforcing effects of arecoline, is necessary before this conclusion can be supported.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34417356      PMCID: PMC8446330          DOI: 10.1097/FBP.0000000000000652

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.277


  45 in total

1.  Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain.

Authors:  BaoXi Gao; Markus Hierl; Kristie Clarkin; Todd Juan; Hung Nguyen; Marissa van der Valk; Hong Deng; Wenhong Guo; Sonya G Lehto; David Matson; Jeff S McDermott; Johannes Knop; Kevin Gaida; Lei Cao; Dan Waldon; Brian K Albrecht; Alessandro A Boezio; Katrina W Copeland; Jean-Christophe Harmange; Stephanie K Springer; Annika B Malmberg; Stefan I McDonough
Journal:  Pain       Date:  2010-02-18       Impact factor: 6.961

2.  Cognitive enhancement in man with ispronicline, a nicotinic partial agonist.

Authors:  Geoffrey C Dunbar; Ramana Kuchibhatla
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

3.  Suppression of behavior by intravenous injections of nicotine or by electric shocks in squirrel monkeys: effects of chlordiazepoxide and mecamylamine.

Authors:  S R Goldberg; R D Spealman
Journal:  J Pharmacol Exp Ther       Date:  1983-02       Impact factor: 4.030

4.  Antinociceptive and pharmacological effects of metanicotine, a selective nicotinic agonist.

Authors:  M I Damaj; W Glassco; M D Aceto; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1999-10       Impact factor: 4.030

5.  Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI).

Authors:  Geoffrey C Dunbar; Fraser Inglis; Ramana Kuchibhatla; Tonmoy Sharma; Mark Tomlinson; James Wamsley
Journal:  J Psychopharmacol       Date:  2007-03       Impact factor: 4.153

6.  Subtype-selective nicotinic agonists enhance olfactory working memory in normal rats: a novel use of the odour span task.

Authors:  Samantha L Rushforth; Claire Allison; Susan Wonnacott; Mohammed Shoaib
Journal:  Neurosci Lett       Date:  2010-01-18       Impact factor: 3.046

7.  Maintenance of behavior by postponement of scheduled injections of nicotine in squirrel monkeys.

Authors:  R D Spealman
Journal:  J Pharmacol Exp Ther       Date:  1983-10       Impact factor: 4.030

8.  Discriminative stimulus properties of arecoline: a new approach for studying central muscarinic receptors.

Authors:  L T Meltzer; J A Rosecrans
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition.

Authors:  Chad R Johnson; Brian D Kangas; Emily M Jutkiewicz; Gail Winger; Jack Bergman; Andrew Coop; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2021-03-12       Impact factor: 4.402

10.  Nicotinic Activity of Arecoline, the Psychoactive Element of "Betel Nuts", Suggests a Basis for Habitual Use and Anti-Inflammatory Activity.

Authors:  Roger L Papke; Nicole A Horenstein; Clare Stokes
Journal:  PLoS One       Date:  2015-10-21       Impact factor: 3.240

View more
  1 in total

1.  Arecoline Induces an Excitatory Response in Ventral Tegmental Area Dopaminergic Neurons in Anesthetized Rats.

Authors:  Qinghui Lan; Peiqing Guan; Chunzheng Huang; Shile Huang; Peiling Zhou; Changzheng Zhang
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.